Abstract
Aim: To validate algorithms based on electronic health data to identify composition of lines of therapy (LOT) in multiple myeloma (MM). Materials & methods: This study used available electronic health data for selected adults within Henry Ford Health (Michigan, USA) newly diagnosed with MM in 2006–2017. Algorithm performance in this population was verified via chart review. As with prior oncology studies, good performance was defined as positive predictive value (PPV) ≥75%. Results: Accuracy for identifying LOT1 (N = 133) was 85.0%. For the most frequent regimens, accuracy was 92.5–97.7%, PPV 80.6–93.8%, sensitivity 88.2–89.3% and specificity 94.3–99.1%. Algorithm performance decreased in subsequent LOTs, with decreasing sample sizes. Only 19.5% of patients received maintenance therapy during LOT1. Accuracy for identifying maintenance therapy was 85.7%; PPV for the most common maintenance therapy was 73.3%. Conclusion: Algorithms performed well in identifying LOT1 – especially more commonly used regimens – and slightly less well in identifying maintenance therapy therein.
Author supplied keywords
Cite
CITATION STYLE
Ailawadhi, S., Romanus, D., Shah, S., Fraeman, K., Saragoussi, D., Buus, R. M., … Berger, A. (2024). Development and validation of algorithms for identifying lines of therapy in multiple myeloma using real-world data. Future Oncology, 20(15), 981–995. https://doi.org/10.2217/fon-2023-0696
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.